A Multicenter, Open-label, Pilot Study of TAK-935 in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs TAK 935 (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms ARCADE
- Sponsors Takeda
- 04 Jan 2019 According to an Ovid Therapeutics media release, the company plans to complete enrollment in this trial in the second half of 2019.
- 17 Dec 2018 According to the Ovid Therapeutics media release, the company will amend the protocols for this study to exclude patients being treated with perampanel and, in light of the mode of action of OV935, the duration of treatment will be extended with the potential to observe the extent of the effects of OV935 on seizure reduction over time.
- 22 Oct 2018 According to an Ovid Therapeutics media release, company has received the 2018 CDKL5 Forum Company Making a Difference Award for initiation of this trial. The first patients have already been enrolled.